Galena linked to Seeking Alpha stock promotion scheme, TheStreet says For the second time the investment website Seeking Alpha has been forced to take action against posters using multiple aliases to tout Galena and this most recent incident links Galena to a stock-promotions firm that published the articles as part of a broader campaign to boost Galena's stock price, according to TheStreet's Adam Feuerstein. Reference Link
Galena receives notice of allowance of improvement patent for NeuVax in Japan Galena Biopharma announced the notice of allowance from the Japanese Patent Office for NeuVax covering the use of NeuVax alone or in combination with other agents to prevent recurrence of any HER2/neu expressing breast cancer tumor having an immunohistochemistry level of 1+ or 2+, or a fluorescence in situ hybridization rating of less than about 2.0. NeuVax is a peptide immunotherapy for the prevention of cancer recurrence and is Galena's lead development agent in multiple ongoing and planned clinical trials. Once issued, the patent will expire in 2027, not including any patent term extensions.